193 related articles for article (PubMed ID: 16601846)
1. Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
Guerrero F; Arnaud C; Nguyen F; Boneu B; Sié P
Thromb Haemost; 2006 Apr; 95(4):728-34. PubMed ID: 16601846
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
3. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
[TBL] [Abstract][Full Text] [Related]
4. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
[TBL] [Abstract][Full Text] [Related]
5. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Graf LL; Welsh CH; Qamar Z; Marlar RA
Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Baig MA
Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
[TBL] [Abstract][Full Text] [Related]
7. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Favaloro EJ; Orsag I; Bukuya M; McDonald D
Pathology; 2002 Aug; 34(4):348-55. PubMed ID: 12190294
[TBL] [Abstract][Full Text] [Related]
8. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
[TBL] [Abstract][Full Text] [Related]
9. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis.
Legnani C; Cini M; Cosmi B; Mattarozzi S; Lo Manto G; Palareti G
Thromb Haemost; 2004 Apr; 91(4):712-8. PubMed ID: 15045132
[TBL] [Abstract][Full Text] [Related]
11. Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Gessoni G; Valverde S; Valle L; Gessoni F; Caruso P; Valle R
Int J Lab Hematol; 2017 Aug; 39(4):418-422. PubMed ID: 28318106
[TBL] [Abstract][Full Text] [Related]
12. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Rodeghiero F; Tosetto A
Ann Intern Med; 1999 Apr; 130(8):643-50. PubMed ID: 10215560
[TBL] [Abstract][Full Text] [Related]
13. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
[TBL] [Abstract][Full Text] [Related]
14. Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
Simkova M; Simko F; Kovacs L
Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.
Jadaon MM; Dashti AA; Lewis HL
Diagn Mol Pathol; 2010 Sep; 19(3):180-3. PubMed ID: 20736749
[TBL] [Abstract][Full Text] [Related]
16. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
[TBL] [Abstract][Full Text] [Related]
17. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.
de Visser MC; Rosendaal FR; Bertina RM
Blood; 1999 Feb; 93(4):1271-6. PubMed ID: 9949170
[TBL] [Abstract][Full Text] [Related]
18. Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay.
Amiral J; Vissac AM; Seghatchian J
Transfus Apher Sci; 2017 Dec; 56(6):906-913. PubMed ID: 29162399
[TBL] [Abstract][Full Text] [Related]
19. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
Castaman G; Tosetto A; Ruggeri M; Rodeghiero F
Br J Haematol; 1999 Jul; 106(1):232-6. PubMed ID: 10444192
[TBL] [Abstract][Full Text] [Related]
20. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
